FDA approves Incyte's treatment for chronic graft-versus-host disease
Rewrites throughout, adds analyst comment in paragraph 9
By Christy Santhosh and Sruthi Narasimha Chari
Aug 14 (Reuters) -The U.S. Food and Drug Administration on Wednesday approved Incyte's INCY.O treatment for chronic graft-versus-host disease (GvHD), a potentially fatal complication that could occur after a stem cell transplant.
The health regulator's nod for axatilimab-csfr, branded as Niktimvo, comes as Incyte faces loss of exclusivity for its biggest-selling drug Jakafi, later this decade.
Jakafi is approved in the U.S. for treating acute GvHD and is considered a remedy for certain bone marrow and blood disorders.
Niktimvo, co-developed with Syndax Pharmaceuticals SNDX.O, is approved for use in adult and pediatric chronic GvHD patients, weighing at least 40 kg, after the failure of at least two prior lines of therapy.
GvHD occurs when immune cells from transplanted tissue recognize the recipient's body as foreign and attack its cells.
It affects about 17,000 patients in the U.S., according to Incyte's estimates.
GvHD might happen during stem cell transplant, a process which replaces healthy blood cells in people who have had theirs destroyed by high doses of chemotherapy or radiation therapy.
The twomain types of GvHD are acute and chronic. Acute GvHD occurs shortly after the transplant, usually within the first 100 days and chronic GvHD typically starts within two years of the transplant and might affect more parts of the body.
BMO Capital Markets analyst Evan Seigerman said he sees a market opportunity of about $200 million in peak sales for treatments in this indication, calling the approval "a comparatively small win" for Incyte against the Jakafi loss of exclusivity.
The approval for Niktimvo was based on a mid-stage trial where 75% of 79 patients treated with the drug showed a partial or complete response to the treatment.
Some other FDA approved treatments for chronic GvHD include AbbVie ABBV.N and Johnson & Johnson's JNJ.N Imbruvica and French drugmaker Sanofi's SASY.PA Rezurock.
Incyte and Syndax said they expect to launch Niktimvo by early first quarter 2025.
Reporting by Sruthi Narasimha Chari and Christy Santhosh in Bengaluru; Editing by Mohammed Safi Shamsi
免责声明: XM Group仅提供在线交易平台的执行服务和访问权限，并允许个人查看和/或使用网站或网站所提供的内容，但无意进行任何更改或扩展，也不会更改或扩展其服务和访问权限。所有访问和使用权限，将受下列条款与条例约束：(i) 条款与条例；(ii) 风险提示；以及(iii) 完整免责声明。请注意，网站所提供的所有讯息，仅限一般资讯用途。此外，XM所有在线交易平台的内容并不构成，也不能被用于任何未经授权的金融市场交易邀约和/或邀请。金融市场交易对于您的投资资本含有重大风险。
所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。
本网站上由XM和第三方供应商所提供的所有内容，包括意见、新闻、研究、分析、价格、其他资讯和第三方网站链接，皆保持不变，并作为一般市场评论所提供，而非投资性建议。所有在线交易平台所发布的资料，仅适用于教育/资讯类用途，不包含也不应被视为适用于金融、投资税或交易相关咨询和建议，或是交易价格纪录，或是任何金融商品或非应邀途径的金融相关优惠的交易邀约或邀请。请确保您已阅读并完全理解，XM非独立投资研究提示和风险提示相关资讯，更多详情请点击 这里。
